Pegaptanib
- Atc Codes:S01LA03
- CAS Codes:222716-86-1
- PHARMGKB ID:222716-86-1
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Macugen; Belgium: Macugen; Czech Republic: Macugen; Denmark: Macugen; Estonia: Macugen; Finland: Macugen; France: Macugen; Germany: Macugen; Greece: Macugen; Hungary: Macugen; Ireland: Macugen; Italy: Macugen; Latvia: Macugen; Lithuania: Macugen; Luxembourg: Macugen; Malta: Macugen; Netherlands: Macugen; Poland: Macugen; Portugal: Macugen; Romania: Macugen; Slovakia: Macugen; Slovenia: Macugen; Spain: Macugen; Sweden: Macugen; UK: Macugen.
North America
Canada: Macugen; USA: Macugen.
Latin America
Brazil: Macugen.
Asia
Japan: Macugen.
Drug combinations
Chemistry
Pegaptanib Sodium: C~294~H~342~F~13~N~107~Na~28~O~188~P~28~ [C~2~H~4~O]~n~. Mw: approx. 50,000.01. (1) RNA, ((2′-Deoxy-2′-fluoro)C-G~m~-G~m~-A-A-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-A~m~-G~m~-(2′-deoxy-2′-fluoro)U-G~m~-A~m~-A~m~-(2′-deoxy-2’2′-fluoro)U-G~m~-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A~m~-(2′-deoxy-2′-fluoro)U-A~m~-(2′-deoxy-2′-fluoro)C-A~m~-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G~m~-(3→3′)-dT), 5′-ester with α,α»-[4,12-dioxo-6-[[[5-(phosphoonoxy)pentyl]amino]carbonyl]-3,13-dioxa-5,11-diaza-1,15-pentadecanediyl]bis[ω-methoxypoly(oxy-1,2-ethanediyl)], sodium salt; (2) 5′-Ester of (2′-deoxy-2′-fluoro)C-G~m~-G~m~-A-A-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)C-A~m~-G~m~-(2′-deoxy-2′-fluoro)U-G~m~-A~m~-A~m~-(2′-deoxy-2′-fluoro)U-G~m~-(2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)U-(2′-deoxy-2′-fluoro)U-A~m~-(2′-deoxy-2′-fluoro)U-A~m~-(2′-deoxy-2′-fluoro)C-A~m~-(2′-deoxy-2′-fluoro)U-(2’2′-deoxy-2′-fluoro)C-(2′-deoxy-2′-fluoro)C-G~m~-(3’→3′)-dT with α,α’-[[(1S)-1-[[5-(phosphonooxy)pentyl]carbamoyl]pentane-1,5-diyl]bis(iminocarbonyl)]bis[ω-methoxypoly(oxyethane-1,2-diyl)] sodium salt. CAS-222716-86-1 (2002).
Pharmacologic Category
EENT Drugs, Miscellaneous. Ophthalmic Agent; Vascular Endothelial Growth Factor Inhibitor. (ATC-Code: S01LA03).
Mechanism of action
Pegaptanib binds to extracellular endothelial growth factor, inhibiting vascular endothelial growth factor from binding to its receptors and thereby suppressing neovascularization and slowing vision loss.
Therapeutic use
Treatment of neovascular (wet) age-related macular degeneration.
Pregnancy and lactiation implications
Teratogenic effects not reported in animal studies. There are no adequate, well-controlled studies in pregnant women. Excretion in breast milk unknown (use caution).
Unlabeled use
Contraindications
Hypersensitivity to pegaptanib or any component of the formulation. Ocular or periocular infection.
Warnings and precautions
Intravitreous injections may be associated with endophthalmitis. Rare hypersensitivity reactions (including anaphylaxis) associated with use. Following injection, intraocular pressure may increase.